Molecular Screening for Urothelial Cancer: How Close We Are?
genomics
liquid biopsy
urothelial cancer
Journal
Global medical genetics
ISSN: 2699-9404
Titre abrégé: Glob Med Genet
Pays: Germany
ID NLM: 101769583
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
medline:
25
5
2023
pubmed:
25
5
2023
entrez:
25
5
2023
Statut:
epublish
Résumé
Early detection of urothelial cancer offers the potential for effective and successful treatment. Despite previous efforts, currently, there is not a well-validated, recommended screening program in any country. This integrative, literature-based review provides details on how recent molecular advances may further advance early tumor detection. The minimally invasive liquid biopsy is capable of identifying tumor material in human fluid samples from asymptomatic individuals. Circulating tumor biomarkers (cfDNA, exosomes, etc.) are very promising and are attracting the interest of numerous studies for the diagnosis of early-stage cancer. However, this approach definitely needs to be refined before clinical implementation. Nevertheless, despite the variety of current obstacles that require further research, the prospect of identifying urothelial carcinoma by a single urine or blood test seems truly intriguing.
Identifiants
pubmed: 37228870
doi: 10.1055/s-0043-1768958
pii: GMG-D-23-00008
pmc: PMC10205394
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
101-104Informations de copyright
The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. ( https://creativecommons.org/licenses/by/4.0/ ).
Déclaration de conflit d'intérêts
Conflict of Interest None declared.
Références
Anal Chem. 2021 Mar 23;93(11):4727-4738
pubmed: 33683116
PLoS One. 2016 Feb 22;11(2):e0149756
pubmed: 26901314
Science. 2018 Feb 23;359(6378):926-930
pubmed: 29348365
Cell. 2017 Feb 9;168(4):571-574
pubmed: 28187279
Cancer. 2006 Nov 1;107(9):2173-9
pubmed: 17029275
BJU Int. 2011 Oct;108(7):1119-23
pubmed: 21426474
Cell. 2017 Oct 19;171(3):540-556.e25
pubmed: 28988769
Lancet. 2011 Jan 8;377(9760):127-38
pubmed: 21183212
Clin Epidemiol. 2018 Aug 29;10:1093-1108
pubmed: 30214314
Urol Oncol. 2018 Jul;36(7):313-320
pubmed: 29573965
Cancer Discov. 2018 Mar;8(3):256
pubmed: 29431695
Gut. 2017 Sep;66(9):1677-1687
pubmed: 27432539
Adv Anat Pathol. 2019 Sep;26(5):313-319
pubmed: 31149909
Int J Mol Sci. 2017 Jul 13;18(7):
pubmed: 28703782
Cancer Cell. 2017 Feb 13;31(2):172-179
pubmed: 28196593
Curr Urol Rep. 2017 Nov 13;18(12):100
pubmed: 29130146
Transl Lung Cancer Res. 2016 Oct;5(5):466-482
pubmed: 27826528
Cancer. 2018 Jun 1;124(11):2269-2270
pubmed: 29878311
Curr Urol Rep. 2018 Oct 24;19(12):102
pubmed: 30357502
Cancer. 2013 Jan 1;119(1):143-9
pubmed: 22736219
Ann Oncol. 2017 Oct 01;28(10):2458-2463
pubmed: 28945843
Eur Urol Oncol. 2021 Dec;4(6):893-903
pubmed: 33975782
Cancer Biol Ther. 2017 Mar 4;18(3):158-165
pubmed: 28121262
Ther Adv Urol. 2016 Jun;8(3):215-33
pubmed: 27247631
Eur Urol Oncol. 2022 Dec;5(6):628-639
pubmed: 36333236
Semin Oncol Nurs. 2017 May;33(2):121-128
pubmed: 28343835
BJU Int. 2016 Apr;117(4):611-7
pubmed: 25891519
Diagnostics (Basel). 2020 Jan 13;10(1):
pubmed: 31941070